Abstract
Atrial fibrillation is the most frequent arrhythmia in clinical practice, reaching 2% of the people in the world and is associated with systemic embolism. Thus, the use of anticoagulants is indicated if CHA2DS2-VASc score ≥2 or in patients with previous transient ischemic attack or stroke. For decades, warfarin, a vitamin K antagonist, was the only choice for chronic oral anticoagulation. Recently, novel oral anticoagulants (NOACs) have been introduced, offering similar (or better) effectiveness, safety, and convenience to the vitamin K antagonists. Dabigatran was the first NOAC approved and is a direct thrombin inhibitor. Rivaroxaban and apixaban are factor Xa inhibitors. They display rapid onset of action, more predictable of pharmacological profile, less interactions with other drugs, lack of significant effects in the diet, and less risk of intracranial hemorrhage than warfarin. Despite that dose adjustment is necessary for patients with chronic kidney disease or according to body weight, these new drugs do not require regular monitoring. There are recommendations for the start and follow-up therapy with NOACs, planning for cardioversion, ablation and surgical interventions and the management of bleeding. This article is a review of the major studies of the NOACs. The clinical use of these drugs in patients with non-valvular atrial fibrillation is presented.
Keywords: Anticoagulants agents, apixaban, atrial fibrillation, dabigatran, rivaroxaban, systemic embolism.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
Volume: 12 Issue: 1
Author(s): Rose M.F.L. da Silva
Affiliation:
Keywords: Anticoagulants agents, apixaban, atrial fibrillation, dabigatran, rivaroxaban, systemic embolism.
Abstract: Atrial fibrillation is the most frequent arrhythmia in clinical practice, reaching 2% of the people in the world and is associated with systemic embolism. Thus, the use of anticoagulants is indicated if CHA2DS2-VASc score ≥2 or in patients with previous transient ischemic attack or stroke. For decades, warfarin, a vitamin K antagonist, was the only choice for chronic oral anticoagulation. Recently, novel oral anticoagulants (NOACs) have been introduced, offering similar (or better) effectiveness, safety, and convenience to the vitamin K antagonists. Dabigatran was the first NOAC approved and is a direct thrombin inhibitor. Rivaroxaban and apixaban are factor Xa inhibitors. They display rapid onset of action, more predictable of pharmacological profile, less interactions with other drugs, lack of significant effects in the diet, and less risk of intracranial hemorrhage than warfarin. Despite that dose adjustment is necessary for patients with chronic kidney disease or according to body weight, these new drugs do not require regular monitoring. There are recommendations for the start and follow-up therapy with NOACs, planning for cardioversion, ablation and surgical interventions and the management of bleeding. This article is a review of the major studies of the NOACs. The clinical use of these drugs in patients with non-valvular atrial fibrillation is presented.
Export Options
About this article
Cite this article as:
Silva M.F.L. da Rose, Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation, Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (1) . https://dx.doi.org/10.2174/187152571201141201091848
DOI https://dx.doi.org/10.2174/187152571201141201091848 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: The Coronary Collateral Circulation – Past, Present and Future)
Current Cardiology Reviews Serum Uric Acid and Risk of Coronary Heart Disease
Current Pharmaceutical Design Cellular and Subcellular Imaging in Live Mice Using Fluorescent Proteins
Current Pharmaceutical Biotechnology Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) Identifying the Cellular Targets of Bioactive Small Molecules with Activity-Based Probes
Current Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Patient Education and Telemedicine in COPD - Update 2015
Current Respiratory Medicine Reviews Epidemiology of Hypertension and Diabetes Mellitus in Latin America
Current Hypertension Reviews Meet Our Editorial Board Member
Current Vascular Pharmacology Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science Health-Care Associated Pneumonia (HCAP): Identification of Low and High-Risk Patients
Current Respiratory Medicine Reviews Molecular Dynamics Simulations of Proteins and Peptides: From Folding to Drug Design
Current Protein & Peptide Science Growth Differentiation Factor-15 as a Biomarker of Obese Pre-diabetes and Type 2 Diabetes Mellitus in Indian Subjects: A Case-control Study
Current Diabetes Reviews Antiangiogenic Agents: Studies on Fumagillin and Curcumin Analogs
Current Pharmaceutical Design PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design